British Patient Capital and Mubadala Investment Company, an Abu Dhabi-based sovereign investor, have a made a co-investment in the SV Biotech Crossover Opportunities Fund (SV BCOF) through the UK’s Life Sciences Investment Programme, a £200 million initiative launched in 2021 to support the growth of UK life sciences businesses.
British Patient Capital and Mubadala Investment Company (Mubadala), an Abu Dhabi-based sovereign investor, have a made a co-investment in the SV Biotech Crossover Opportunities Fund (SV BCOF) through the UK’s Life Sciences Investment Programme (LSIP), a £200 million initiative launched in 2021 to support the growth of UK life sciences businesses.
According to manager SV Health Investors, SV BCOF is targeting growth-stage, biotechnology companies developing transformative therapies, and will focus on UK businesses that have the potential to positively impact society by addressing major unmet clinical needs.
British Patient Capital is a cornerstone investor in the fund and has committed a total of $48.6m.
To date, six investments have been completed through SV BCOF, including five into UK-based companies: Bicycle, a company developing a brand-new class of precision-guided therapeutics to target intractable cancers; Quell Therapeutics, a specialist in engineered T-regulatory cell therapies for serious medical conditions driven by overactivity of the immune system; Pulmocide, a biopharmaceutical company treating common but hard-to-treat respiratory infections; and EyeBio, which is developing a new generation of therapies for eye diseases to protect, restore, and improve vision for people who are underserved by available therapies.
